KIT and metastatic melanoma: Non-randomized trials of KIT inhibitors (ie, imatinib) in metastatic melanoma patients with a Kit mutation have reported response rates of approximately 10%-30%, with higher rates (up to 50%) reported for patients specifically with recurrent mutations seen in this disease (ie, L576P, K642E).13 Treatment with KIT inhibitors is recommended for metastatic melanoma patients with a Kit mutation who have progressed on or cannot tolerate immunotherapy.26